Skip to main content
Premium Trial:

Request an Annual Quote

Here's a Bump in the Business Plan

Following in New York's footsteps, California's state health department has sent cease-and-desist orders to 13 consumer genomics companies, reports Forbes.com. In California, the law is that laboratory tests -- including genetic tests -- have to be ordered by a physician and must be validated for accuracy and medical utility. A spokeswoman said that California's investigation was prompted by consumer complaints. "The consumers were unhappy about the accuracy [of the tests] and thought they cost too much," she said.

At Genetic Future, Daniel predicts that this is just the beginning. "To a large extent what's going on here is a turf war between proponents of the old-school medical regulation model and upstart advocates of the free information paradigm of the Google generation."

 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.